^
    6d
    SAFARi: A clinical study to compare the safety and tolerability of two formulations of a new Systemic Sclerosis drug in Healthy Participants - Part B (ACTRN12625000744459)
    P1, N=33, Completed, Certa Therapeutics Pty Ltd | Not yet recruiting --> Completed
    Trial completion • Trial initiation date
    7d
    Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (clinicaltrials.gov)
    P1/2, N=8, Terminated, M.D. Anderson Cancer Center | Completed --> Terminated; Insufficient accrual
    Trial termination
    |
    HR positive
    |
    bintrafusp alfa (M7824) • pimasertib (AS703026)
    12d
    TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma. (PubMed, Int J Mol Sci)
    Data obtained clearly highlighted how TGF-β inhibition, through the silencing or treatment of MPM cells with antibody anti-TGF-β (Fresolimumab), significantly reduces cell proliferation (MTT, PCNA) and prevents metastasis, reducing EMT and decreasing the invasiveness and migration of MPM cells...Taken as a whole, targeting TGF-β will represent a starting point for future improvements in MPM management. This is particularly important as we foresee a growing increase in MPM in the coming years.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • PCNA (Proliferating cell nuclear antigen)
    |
    fresolimumab (GC 1008)
    14d
    A case report of idiopathic pulmonary fibrosis concurrent with EGFR 19 deletion lung adenocarcinoma. (PubMed, Transl Cancer Res)
    The patient was managed with a combination therapy of icotinib (an EGFR-TKI) and Pirfenidone (an anti-fibrotic agent). Tumor molecular testing is also important in patients with NSCLC concurrent with IPF. Furthermore, it provides preliminary clinical evidence suggesting that, with careful monitoring and concomitant anti-fibrotic therapy, EGFR-TKIs like Icotinib may represent a viable treatment option for patients co-existing with IPF and EGFR-mutated NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    Conmana (icotinib)
    14d
    A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=270, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    emavusertib (CA-4948) • Reblozyl (luspatercept-aamt) • Retacrit (epoetin alfa-epbx)
    14d
    A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain (clinicaltrials.gov)
    P=N/A, N=1300, Active, not recruiting, Bristol-Myers Squibb
    New trial
    |
    lenalidomide • Reblozyl (luspatercept-aamt)
    14d
    Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Dana-Farber Cancer Institute
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)
    16d
    SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (clinicaltrials.gov)
    P3, N=815, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    Winrevair (sotatercept-csrk)
    16d
    ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov)
    P3, N=300, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    elritercept (KER-050)
    19d
    PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects (clinicaltrials.gov)
    P1, N=116, Completed, PureTech
    New P1 trial
    20d
    Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors. (PubMed, Biomater Res)
    To counteract this resistance mechanism, we developed a TME-responsive nanogel (pirfenidone@nanogel-hyaluronidase-anti-PD-L1 [PFD@NGHP]) for rescuing radiosensitization...This effect synergized radiotherapy to sustain tumor regression and generate abscopal effects. Collectively, our study demonstrates that PFD@NGHP targets the TGF-β1-PD-L1 axis in a cascading manner, offering a promising clinical strategy to overcome the adaptive radioresistance of irradiated pancreatic ductal adenocarcinoma while providing a potential platform for translational nanomedicine evaluation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 overexpression
    21d
    The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Reblozyl (luspatercept-aamt)